3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
1
Lymphoma, T-Cell, Peripheral
1
Hodgkin Disease
1
Interventions
Cyclophosphamide
24
Mycophenolic Acid
15
fludarabine phosphate
14
fludarabine
13
Whole-Body Irradiation
13
Tacrolimus
12
Rituximab
12
Melphalan
12
Filgrastim
11
Cyclosporine
11
Busulfan
11
Radiotherapy
10
Peripheral Blood Stem Cell Transplantation
10
Antilymphocyte Serum
10
Methotrexate
9
Doxorubicin
9
Gemcitabine
8
Etoposide
8
Brentuximab Vedotin
8
Sirolimus
7
pembrolizumab
6
Vinblastine
6
Nivolumab
6
Methylprednisolone
6
Granulocyte Colony-Stimulating Factor
6
Alemtuzumab
6
Dacarbazine
5
Cytarabine
5
Cord Blood Stem Cell Transplantation
5
Carmustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hodgkin Disease
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts